KRAS inhibitor testing solutions with patient-derived organoids
Our cutting-edge KRAS inhibitor testing screens use patient-derived organoids (PDO), clinically relevant models to test lead compound efficacy. This platform addresses challenges in KRAS-targeted drug discovery and development by offering predictive screens using a diverse PDO biobank to improve clinical success rates.
Key benefits of the toxicology screen:
- Preserves the genetic and functional characteristics of the original tumor
- Uses models derived directly from patient tissues, which provides better translatability
The challenge of targeting KRAS
KRAS remains one of the most challenging oncogenic drivers in cancer therapy. Despite recent breakthroughs in KRAS-targeted inhibitors, drug development continues to be hindered by tumor heterogeneity, adaptive resistance, and limited preclinical models. Mutations such as G12D, G12C, and G12V drive aggressive tumor growth across colorectal, pancreatic, lung, and ovarian cancers, but conventional models fail to accurately predict patient responses. Addressing these challenges requires a preclinical system that faithfully replicate tumor diversity and resistance mechanisms to optimize therapeutic strategies.
Advantages of using patient-derived organoid technology for KRAS research
Our PDO screening platform provides a three-dimensional, clinically relevant, in vitro system that preserves the genetic, phenotypic, and functional characteristics of the original tumor. Unlike more traditional 2D cell lines or animal models, PDOs allow for:
- Better translatability: Models derived directly from patient tissues
- High-throughput screening capabilities: Scalable testing for efficacy and resistance
- Longitudinal studies: Evaluation of acquired resistance over time
- Multi-omic data integration: Generating deeper insights into tumor biology and drug response
We offer a range of KRAS-targeted solutions designed to accelerate drug discovery and development with high clinical relevance.
Comprehensive KRAS inhibitor testing services
Our advanced KRAS Inhibitor Testing Solutions are designed to accelerate drug discovery and development.
KRASmut PDO Screen
To meet the needs for rapid testing of pan-KRAS inhibitors we have developed the KRASmut PDO Screen - a pre-set, recurrent screening platform that leverages a panel of 25 PDOs carrying clinically relevant KRAS mutations, such as G12D, G12C, and G12V, to evaluate compound efficacy and optimize therapeutic strategies. This assay enables:
- Rapid, cost-effective testing of KRAS inhibitors against a diverse collection of patient-derived models
- Comparative efficacy analysis across multiple cancer indications and clinically relevant KRAS mutations
- Standardized, reproducible data to streamline preclinical decision-making
KRAS PDO Biobank
To meet expanded needs, we also provide a comprehensive KRASmut PDO Biobank of over 50 PDOs from colorectal, pancreatic, lung, and ovarian cancer models, featuring key KRAS driver mutations (G12D, G12C, G12V) and providing unmatched diversity and precision for preclinical research. These models can be selected for a customized KRASmut screening panel and provide:
- Diverse tumor backgrounds to assess drug response across cancer types
- Genetically matched control organoids for comparative analysis
- Robust in vitro preclinical validation before moving to in vivo studies
Conclusion
We empower drug developers with clinically relevant preclinical models to advance KRAS-targeted therapies. Whether you need a diverse PDO biobank or high-throughput KRAS screening, our platform provides the predictive tools necessary to improve clinical success rates.
Need more information? Contact a specialist here.